Evidences for the Anti-panic Actions of Cannabidiol Vanessa P. Soares and Alline C. Campos Current Neuropharmacology, 2017, 15, 291-299 DOI : 10.2174/1570159X14666160509123955 Abstract : Background : Panic disorder (PD) is a disabling psychiatry condition that affects approximately 5% of the worldwide population. Currently, long-term selective serotonin reuptake inhibitors (SSRIs) are the first-line treatment for PD; however, the common side-effect profiles and drug interactions may provoke patients to abandon the treatment, leading to PD symptoms relapse. Cannabidiol (CBD) is the major non-psychotomimetic constituent of the Cannabis sativa plant with antianxiety properties that has been suggested as an alternative for treating anxiety disorders. The aim of the [...]
Lire la suiteImproved Social Interaction, Recognition and Working Memory with Cannabidiol Treatment in a Prenatal Infection (poly I:C) Rat Model Ashleigh L. Osborne, Nadia Solowij, Ilijana Babic, Xu-Feng Huang and Katrina Weston-Green Neuropsychopharmacology, 2017, 42, 1447–1457 0893-133X/17 www.neuropsychopharmacology.org doi:10.1038/npp.2017.40 Neuropsychiatric disorders such as schizophrenia are associated with cognitive impairment, including learning, memory and attention deficits. Antipsychotic drugs are limited in their efficacy to improve cognition; therefore, new therapeutic agents are required. Cannabidiol (CBD), the non-intoxicating component of cannabis, has anti-inflammatory, neuroprotective and antipsychotic-like properties; however, its ability to improve the cognitive deficits of schizophrenia remains unclear. Using a prenatal infection model, we examined the effect of chronic CBD [...]
Lire la suiteCannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia : A Multicenter Randomized Controlled Trial Philip McGuire, F.R.C.Psych., F.Med.Sci., Philip Robson, M.R.C.P., F.R.C.Psych., Wieslaw Jerzy Cubala, M.D., Ph.D., Daniel Vasile, M.D., Ph.D., Paul Dugald Morrison, Ph.D., M.R.C.Psych., Rachel Barron, B.Vet.Med., M.R.C.V.S., Adam Taylor, Ph.D., Stephen Wright, F.R.C.P.(Edin), F.F.P.M. American Journal of Psychiatry, 2018, 175, 225–231. doi: 10.1176/appi.ajp.2017.17030325 Objective : Research in both animals and humans indicates that cannabidiol (CBD) has antipsychotic properties. The authors assessed the safety and effectiveness of CBD in patients with schizophrenia. Method : In an exploratory double-blind parallel-group trial, patients with schizophrenia were randomized in a 1:1 ratio to receive CBD (1000 [...]
Lire la suiteLSD Changes Something About The Way You Perceive Time We measure time in set amounts— seconds, minutes, and hours. But the way time feels is more slippery. Shayla Love, December 3, 2018, Grotmarsel/ Getty This story was first published by Tonic, VICE's health site. You can now find the same great health content right here at vice.com. In 2015, when cognitive neuroscientist Devin Terhune was hit by a car, the impact took less than a second, but he felt it to be much longer. “I was riding [my bike] very fast, and so when I hit the car I went flying back around 15 feet or more,” he [...]
Lire la suiteThe Ethics of Taking the Drugs You Study Should psychedelic scientists trip on the drugs they research? Shayla LOVE VICE.com, May 14 2019 From 1960 to 1962, the Harvard Psilocybin Project conducted unconventional experiments, like giving psilocybin to prison inmates to see if it would reduce recidivism, or doling it out to theology students to provoke a religious experience. Led by Timothy Leary and Richard Alpert, their goal was to test the potential applications of the active ingredient in magic mushrooms. Leary was a clinical psychologist and professor at Harvard. After taking mushrooms in 1960, he “declared that he learned more in the following five [...]
Lire la suiteMental health of a self-selected sample of psychedelic users and self-medication practices with psychedelics Natasha L. MASON and Kim P. C. KUYPERS Journal of Psychedelic Studies, 2018, 2, (1), pp. 45–52 DOI: 10.1556/2054.2018.006 Background : A substantial number of people worldwide suffer from mental health problems during their lifetime. First-line treatments are not effective for everybody. Recent studies suggest that psychedelic drugs have high therapeutic potential for a variety of mental disorders. Aims : This survey study aimed to assess the tendency of psychedelic users to self-medicate with psychedelics and to compare the effectiveness of self-administered psychedelics to treat their disorder and the treatment offered [...]
Lire la suiteA phenomenological analysis of the subjective experience elicited by ibogaine in the context of a drug dependence treatment EDUARDO EKMAN SCHENBERG, MARIA ANGÉLICA DE CASTRO COMIS, JOÃO FELIPE MOREL ALEXANDRE, LUÍS FERNANDO TÓFOLI, BRUNO DANIEL RASMUSSEN CHAVES, DARTIU XAVIER DA SILVEIRA Journal of Psychedelic Studies, 2017, 1, (2), pp. 74–83 DOI: 10.1556/2054.01.2017.007 Objective : This report documents the phenomenology of the subjective experiences of 22 patients with substancerelated disorders who were involved in a treatment combining cognitive–behavioral therapy and hospital sessions with ibogaine in Brazil. Methods: Participants underwent a one-to-one semi structured interview exploring the subjective effects of ibogaine. We employed interpretative phenomenological analysis [...]
Lire la suitePsychedelic drugs in the treatment of anxiety, depression and addiction Tor-Morten Kvam, Lowan H. Stewart & Ole A. Andreassen Tidsskriftet, Den Norske Legeforening, November 2018 https://www.researchgate.net/publication/332136512 B A C K G R O U N D There is growing interest in the use of psychedelic drugs for the treatment of mental disorders. The drugs are considered safe when administered within a clinical framework. Older studies performed prior to 1970 had methodological shortcomings, but studies in recent years have shown promising results regarding the use of psychedelic drugs in unipolar depression, depression in life-threatening illness, anxiety and addiction. The aim of this literature review is to [...]
Lire la suiteCan psychedelics be the treatment for the crisis in psychopharmacology ? Genís Ona, José Carlos Bouso ICEERS Foundation, Preprint · January 2019 DOI: 10.20944/preprints201901.0249.v1 Keywords : Mental health, psychedelics, psychopharmacology, psychiatry, innovative 1. Introduction For the past few years, we have been witnessing a crisis in the field of psychopharmacology. Generally, it takes a decade and up to a billion dollars in investment to get a drug on the market. Furthermore, the majority of new drugs are ruled out during the pre-clinical phase. Less than 20% of the selected drugs make it to Phase-III evaluation involving humans. Drug development has never been an easy task. However, [...]
Lire la suiteREBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics R. L. Carhart-Harris and K. J. Friston Pharmacological Reviews, 2019, 71, 316–344 https://doi.org/10.1124/pr.118.017160 Significance Statement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 317 I. Introduction. . . . . . . . . . . . . . . . . . . . . . . . . [...]
Lire la suite